An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the appointment of Laureen DeBuono to its Board of Directors, succeeding Kenneth Clark, who has resigned. DeBuono brings extensive executive experience in driving growth and shareholder value in life sciences and medical technology sectors. She has previously held positions at Rodan+Fields and served as CEO of govino, LLC. Her appointment aims to enhance the commercial growth of the CellFX® System in dermatology and expand the company’s multi-specialty bioelectric medicine profile.
Positive
Laureen DeBuono's extensive experience in life sciences and medical technology may drive company growth.
Her appointment is expected to strengthen the leadership team and support the commercial expansion of the CellFX System.
Negative
Kenneth Clark's resignation may lead to concerns regarding continuity and experience within the board.
HAYWARD, Calif.--(BUSINESS WIRE)--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Laureen DeBuono to its Board of Directors. Concurrent to Ms. DeBuono’s appointment, Kenneth Clark has resigned from the Board of Directors.
“We are delighted and honored to welcome Laureen to the Pulse Biosciences Board,” said Robert Duggan, Chairman of the Pulse Biosciences Board of Directors. “Laureen is an accomplished executive with a track record of driving growth and creating shareholder value through operational, financial and strategic execution for multiple life sciences, medical technology, and aesthetics companies. We look forward to her insight as we grow the CellFX System’s commercial footprint in dermatology and further expand as a multi-specialty bioelectric medicine company. We also want to thank Ken for his four years of exemplary service and guidance. His steadfast support and indelible surge to pursue success has inspired all Pulse Biosciences’ stakeholders. Rest assured, we will undoubtably use his willingness to consult with us in the future.”
Ms. DeBuono currently serves as a Managing Partner at FLG Partners LLC, the leading interim executive and Board advisory firm in Silicon Valley, which she joined in 2011. As an Advisor to the Board of Directors and Interim CFO, she helped lead the growth of Rodan+Fields, a premium skincare company with a unique sales business model between 2014 and 2016. Most recently she also served as CEO and Board Member of govino, LLC, a global CPG company from 2018 through January 2020. Also in 2018, Ms. DeBuono joined HotelTonight as a Board Advisor and Interim CFO, to advise and oversee its sale to AirBnB in April 2019. Previously, Ms. DeBuono served in various executive capacities at multiple healthcare, medical technology and CPG companies from 1992-2017.
Ms. DeBuono received a BA from Duke University, an MA from Stanford University, and a JD from the New York University School of Law. Ms. DeBuono is a member of the State Bar of California. She has also attended the Stanford Directors’ College and is a certified Board Leadership Fellow with the National Association of Corporate Directors.
“What attracted me to Pulse Biosciences is the diverse opportunity set for Nano-Pulse Stimulation technology and the experienced leadership team,” said Laureen DeBuono, Director, Pulse Biosciences. “There is great potential for this platform and I am excited to leverage my past experiences with growth companies to help Pulse Biosciences scale operationally, financially and strategically.”
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit pulsebiosciences.com to learn more.
To stay informed about the CellFX System, please visit CellFX.com and sign-up for updates.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
What is the significance of Laureen DeBuono's appointment to Pulse Biosciences' Board?
Laureen DeBuono's appointment is significant as she brings a wealth of experience in life sciences, expected to drive growth and enhance shareholder value for Pulse Biosciences (PLSE).
Who resigned from the Board of Directors at Pulse Biosciences?
Kenneth Clark has resigned from the Board of Directors at Pulse Biosciences (PLSE).
How does Laureen DeBuono's experience benefit Pulse Biosciences?
DeBuono's experience in operational and strategic execution in medical technology and life sciences is anticipated to bolster Pulse Biosciences' growth strategy and commercial execution.
What does the leadership change mean for Pulse Biosciences' future?
The leadership change may introduce fresh perspectives and strategies, potentially enhancing operational and financial performance in the long term.
